vs
ICU MEDICAL INC（ICUI）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是RBC Bearings INC的1.2倍（$540.7M vs $461.6M），RBC Bearings INC净利率更高（14.6% vs -2.9%，领先17.5%），RBC Bearings INC同比增速更快（17.0% vs -14.1%），RBC Bearings INC自由现金流更多（$99.1M vs $36.0M），过去两年RBC Bearings INC的营收复合增速更高（5.6% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
ICUI vs RBC — 直观对比
营收规模更大
ICUI
是对方的1.2倍
$461.6M
营收增速更快
RBC
高出31.2%
-14.1%
净利率更高
RBC
高出17.5%
-2.9%
自由现金流更多
RBC
多$63.1M
$36.0M
两年增速更快
RBC
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $461.6M |
| 净利润 | $-15.7M | $67.4M |
| 毛利率 | 37.5% | 44.3% |
| 营业利润率 | 1.0% | 22.3% |
| 净利率 | -2.9% | 14.6% |
| 营收同比 | -14.1% | 17.0% |
| 净利润同比 | 34.0% | 16.4% |
| 每股收益（稀释后） | $-0.63 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIRBC
| Q4 25 | $540.7M | $461.6M | ||
| Q3 25 | $537.0M | $455.3M | ||
| Q2 25 | $548.9M | $436.0M | ||
| Q1 25 | $604.7M | $437.7M | ||
| Q4 24 | $629.8M | $394.4M | ||
| Q3 24 | $589.1M | $397.9M | ||
| Q2 24 | $596.5M | $406.3M | ||
| Q1 24 | $566.7M | $413.7M |
净利润ICUIRBC
| Q4 25 | $-15.7M | $67.4M | ||
| Q3 25 | $-3.4M | $60.0M | ||
| Q2 25 | $35.3M | $68.5M | ||
| Q1 25 | $-15.5M | $72.7M | ||
| Q4 24 | $-23.8M | $57.9M | ||
| Q3 24 | $-33.0M | $54.2M | ||
| Q2 24 | $-21.4M | $61.4M | ||
| Q1 24 | $-39.5M | — |
毛利率ICUIRBC
| Q4 25 | 37.5% | 44.3% | ||
| Q3 25 | 37.4% | 44.1% | ||
| Q2 25 | 37.9% | 44.8% | ||
| Q1 25 | 34.7% | 44.2% | ||
| Q4 24 | 36.1% | 44.3% | ||
| Q3 24 | 34.8% | 43.7% | ||
| Q2 24 | 34.8% | 45.3% | ||
| Q1 24 | 32.7% | 43.1% |
营业利润率ICUIRBC
| Q4 25 | 1.0% | 22.3% | ||
| Q3 25 | 2.6% | 21.5% | ||
| Q2 25 | 1.9% | 23.2% | ||
| Q1 25 | 2.1% | 23.0% | ||
| Q4 24 | 6.0% | 21.7% | ||
| Q3 24 | 1.4% | 21.6% | ||
| Q2 24 | 1.3% | 24.0% | ||
| Q1 24 | -1.9% | 22.8% |
净利率ICUIRBC
| Q4 25 | -2.9% | 14.6% | ||
| Q3 25 | -0.6% | 13.2% | ||
| Q2 25 | 6.4% | 15.7% | ||
| Q1 25 | -2.6% | 16.6% | ||
| Q4 24 | -3.8% | 14.7% | ||
| Q3 24 | -5.6% | 13.6% | ||
| Q2 24 | -3.6% | 15.1% | ||
| Q1 24 | -7.0% | — |
每股收益（稀释后）ICUIRBC
| Q4 25 | $-0.63 | $2.13 | ||
| Q3 25 | $-0.14 | $1.90 | ||
| Q2 25 | $1.43 | $2.17 | ||
| Q1 25 | $-0.63 | $2.33 | ||
| Q4 24 | $-0.97 | $1.82 | ||
| Q3 24 | $-1.35 | $1.65 | ||
| Q2 24 | $-0.88 | $1.90 | ||
| Q1 24 | $-1.63 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $2.1B | $3.3B |
| 总资产 | $4.1B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ICUIRBC
| Q4 25 | — | $107.6M | ||
| Q3 25 | — | $91.2M | ||
| Q2 25 | — | $132.9M | ||
| Q1 25 | — | $36.8M | ||
| Q4 24 | $308.6M | — | ||
| Q3 24 | $312.5M | — | ||
| Q2 24 | $302.6M | $76.8M | ||
| Q1 24 | $251.4M | $63.5M |
总债务ICUIRBC
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
股东权益ICUIRBC
| Q4 25 | $2.1B | $3.3B | ||
| Q3 25 | $2.1B | $3.2B | ||
| Q2 25 | $2.1B | $3.1B | ||
| Q1 25 | $2.0B | $3.0B | ||
| Q4 24 | $2.0B | $2.9B | ||
| Q3 24 | $2.0B | $2.9B | ||
| Q2 24 | $2.0B | $2.8B | ||
| Q1 24 | $2.1B | $2.8B |
总资产ICUIRBC
| Q4 25 | $4.1B | $5.1B | ||
| Q3 25 | $4.1B | $5.1B | ||
| Q2 25 | $4.1B | $4.8B | ||
| Q1 25 | $4.2B | $4.7B | ||
| Q4 24 | $4.2B | $4.7B | ||
| Q3 24 | $4.3B | $4.7B | ||
| Q2 24 | $4.3B | $4.7B | ||
| Q1 24 | $4.3B | $4.7B |
负债/权益比ICUIRBC
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $99.1M |
| 自由现金流率自由现金流/营收 | 6.6% | 21.5% |
| 资本支出强度资本支出/营收 | 4.6% | 5.0% |
| 现金转化率经营现金流/净利润 | — | 1.81× |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIRBC
| Q4 25 | $60.6M | $122.1M | ||
| Q3 25 | $56.7M | $88.4M | ||
| Q2 25 | $11.2M | $120.0M | ||
| Q1 25 | $51.3M | — | ||
| Q4 24 | $40.2M | $84.0M | ||
| Q3 24 | $36.1M | — | ||
| Q2 24 | $82.0M | $97.4M | ||
| Q1 24 | $45.8M | — |
自由现金流ICUIRBC
| Q4 25 | $36.0M | $99.1M | ||
| Q3 25 | $27.6M | $71.7M | ||
| Q2 25 | $-8.5M | $104.3M | ||
| Q1 25 | $36.7M | — | ||
| Q4 24 | $16.1M | $73.6M | ||
| Q3 24 | $16.2M | — | ||
| Q2 24 | $62.5M | $88.4M | ||
| Q1 24 | $29.9M | — |
自由现金流率ICUIRBC
| Q4 25 | 6.6% | 21.5% | ||
| Q3 25 | 5.1% | 15.7% | ||
| Q2 25 | -1.5% | 23.9% | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 2.6% | 18.7% | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 10.5% | 21.8% | ||
| Q1 24 | 5.3% | — |
资本支出强度ICUIRBC
| Q4 25 | 4.6% | 5.0% | ||
| Q3 25 | 5.4% | 3.7% | ||
| Q2 25 | 3.6% | 3.6% | ||
| Q1 25 | 2.4% | 3.2% | ||
| Q4 24 | 3.8% | 2.6% | ||
| Q3 24 | 3.4% | 4.1% | ||
| Q2 24 | 3.3% | 2.2% | ||
| Q1 24 | 2.8% | — |
现金转化率ICUIRBC
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | 0.32× | 1.75× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.59× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
